Paclitaxel for Injection(Albumin-Bound)
Albumin-bound paclitaxel takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility
Blockbuster drugs in tumor chemotherapy, simultaneous filing in China and Europe
Albumin-bound paclitaxel(Apexelsin) takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility, featured by "Three Highs and One Low", i.e. high dose, high distribution in tumor tissue, high efficacy, and low toxicity. Albumin-bound paclitaxel is recommended by the NCCN and CSCO guidelines for the treatment of breast cancer. It is the only product in China that is applied simultaneously in China, the United States, and the European Union and the NDA in China and European Union has been accepted for review.
Indications
Metastatic breast cancer after failure of combination chemotherapy or breast cancer within 6 months after adjuvant chemotherapy.
Recommended reading
Unlocking the Power of Albumin-Bound Paclitaxel: Quality, Affordability, and Innovation
Exploring the Power of Albumin-Bound Paclitaxel: A Breakthrough in Cancer Treatment
Related products
-
The Latest 5-in-1 Car Jump Starter and Tire Inflator
Contact UsThis innovative device combines four essential functions in one compact unit, ensuring you’re well-equipped for any roadside emergency or outdoor adventure.
-
JA Solar Deep Blue 3.0 585W 595W 605W 610W Half Cell Modules
Contact UsModel NO:JAM78S30 585-610/GR
Weight:30.5 kg
Transport Package:Wooden Pallet and Carton Packing
Specification:2456±2mm*1134±2mm*35±1mm
Trademark:JA solar
Origin:China -
Recombinant Collagen Repair Mask
Contact UsCOLLAGEN SUPPLEMENTATION – A SCIENTIFIC SOLUTION TO AGING SKIN
-
Durable moving bed carpet
Contact UsThe vacuum cleaner mobile test bench, model ZYXCQ-8A, is an intelligent aging test bench designed and implemented based on the complete machine testing requirements of the IEC-60312 standard.
Reviews
There are no reviews yet.